REFERENCES
1. Alhuneafat L, Guha A, Blaes A, Konety SH. Cancer and cardiovascular disease: shared risk factors, mechanisms, and clinical implications: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2025;7:453-69.
2. Cleary S, Rosen SD, Gilbert DC, Langley RE. Cardiovascular health: an important component of cancer survivorship. BMJ Oncol. 2023;2:e000090.
3. Boudoulas KD, Triposkiadis F, Gumina R, Addison D, Iliescu C, Boudoulas H. Cardiovascular disease, cancer, and multimorbidity interactions: clinical implications. Cardiology. 2022;147:196-206.
4. De Boer RA, Meijers WC, Van Der Meer P, Van Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019;21:1515-25.
5. Battistoni A, Volpe M. Recent warnings about antihypertensive drugs and cancer risk: where do they come from? Eur Cardiol. 2020;15:e16.
6. Zuin M, Nohria A, Henkin S, Krishnathasan D, Sato A, Piazza G. Pulmonary embolism-related mortality in patients with cancer. JAMA Netw Open. 2025;8:e2460315.
7. Gardezi SA, Sachdeva N, Rampurawala IM, et al. Trends and disparities in inflammatory bowel disease and cardiovascular disease-related mortality in the United States from 1999 to 2023: A CDC WONDER analysis. Int J Cardiol Cardiovasc Risk Prev. 2025;26:200438.
8. Kumar A, Khadke S, Alkindi S, et al. Particulate matter 2.5 pollution impact on comorbid cancer and cardiovascular disease mortality in the U.S. JACC Adv. 2024;3:101106.
9. Ahmed M, Javaid H, Shafiq A, et al. Trends and disparities in coronary artery disease and obesity‐related mortality in the united states from 1999-2022. Endocrino Diabet Metabol. 2024;7:e70010.
10. Ansari HUH, Mahboob E, Samad MA, et al. Temporal trends and disparities in atherosclerosis-associated cerebrovascular disease mortality in the United States, 1999-2020. Curr Probl Cardiol. 2025;50:102935.
11. National intercensal datasets: 2000-2010. Available from: https://www.census.gov/data/datasets/time-series/demo/popest/intercensal-2000-2010-national.html [Last accessed on 20 May 2026].
12. Kim H, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-51.
13. Rakisheva A, Farmakis D, Attanasio A, et al. Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2025;27:2084-99.
14. Thuny F, Naidoo J, Neilan TG. Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J. 2022;43:4458-68.
15. Wilcox NS, Amit U, Reibel JB, Berlin E, Howell K, Ky B. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol. 2024;21:617-31.
16. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457-67.
17. Song S, Guo C, Wu R, et al. Impact of the COVID-19 pandemic on cardiovascular mortality and contrast analysis within subgroups. Front Cardiovasc Med. 2024;11:1279890.
18. Koo TH. Trends and disparities of diverticular disease mortality in the United States before and during the COVID-19 era: estimates from the Centers for Disease Control WONDER database. Ann gastroenterol. 2025;38:428-39.
19. Ebert BL, Libby P. Clonal hematopoiesis confers predisposition to both cardiovascular disease and cancer: a newly recognized link between two major killers. Ann Intern Med. 2018;169:116-7.
20. Ng M, Dai X, Cogen RM, et al. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050. Lancet. 2024;404:2278-98.
